The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

Sponsor: Tanja A. Gruber, MD

Protocol: POE23-01

Principal investigator: Tanja A. Gruber, MD

Site: 27 sites across North America

Estimated accrual years: 5.0

This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study.

This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated dose of all 3 drugs when given in combination. A preliminary estimate of efficacy through a dose expansion phase is a secondary aim.

Sponsor: Dr. Kamens

Protocol: POE22-01

Principal investigator: Jennifer Kamens, MD

Site: Stanford University

Estimated accrual years: 2.0

Sponsor: Genentech

Protocol: GO40871

Estimated accrual years: 5 years (in 3 phases)

A Phase I/II study of Neratinib in pediatric patients with relapsed or refractory solid tumors or hematologic malignancies

Sponsor: Puma

Protocol: POE16-01

Principal investigator: Tanya Trippett, MD

Site: Memorial Sloan Kettering Cancer Center

Estimated accrual years: 1.0 (Phase I); 1.5 (Phase II)